Brief: Nexalin Technology Completes FDA Q-Submission Meeting For Gen-2 Sync
03/12/2025 13:07
Dec 3 (Reuters) - Nexalin Technology Inc NXL.O: NEXALIN TECHNOLOGY COMPLETES FDA Q-SUBMISSION MEETING FOR GEN-2 SYNC™ NEUROSTIMULATION CONSOLE IN ALZHEIMER’S DISEASE PROGRAM NEXALIN TECHNOLOGY INC - PLANS U.S. PILOT AND PIVOTAL STUDIES FOR GEN-2 SYNC NEXALIN TECHNOLOGY INC - POTENTIAL DE NOVO PATHWAY DISCUSSED FOR NEXALIN'S TECHNOLOGY NEXALIN TECHNOLOGY INC - REVIEWED ENDPOINTS FOR ALZHEIMER'S OUTCOMES INCLUDING COGNITIVE ASSESSMENTS Source text: ID:nGNE51cXFr Further company coverage: NXL.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nexalin Technology
See all newsBrief: Nexalin Technology Regains Compliance With Nasdaq Minimum Bid Price Requirement Nasdaq Hearings Panel Grants Request For Continued Listing
NASDAQ RESUMED AT 12:48 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:43 PM
NASDAQ RESUMED AT 10:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:24 AM